Karyopharm Therapeutics Inc. (KPTI)

NASDAQ: KPTI · IEX Real-Time Price · USD
0.869
-0.048 (-5.26%)
Jul 19, 2024, 11:42 AM EDT - Market open
-5.26%
Market Cap 107.47M
Revenue (ttm) 140.46M
Net Income (ttm) -146.34M
Shares Out 124.62M
EPS (ttm) -1.27
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 332,301
Open 0.910
Previous Close 0.918
Day's Range 0.862 - 0.923
52-Week Range 0.617 - 1.950
Beta 0.21
Analysts Buy
Price Target 4.60 (+429.22%)
Earnings Date Jul 31, 2024

About KPTI

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myelom... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Nov 6, 2013
Employees 325
Stock Exchange NASDAQ
Ticker Symbol KPTI
Full Company Profile

Financial Performance

In 2023, KPTI's revenue was $146.03 million, a decrease of -7.03% compared to the previous year's $157.07 million. Losses were -$143.10 million, -13.43% less than in 2022.

Financial Statements

Analyst Forecast

According to 5 analysts, the average rating for KPTI stock is "Buy." The 12-month stock price forecast is $4.6, which is an increase of 429.22% from the latest price.

Price Target
$4.6
(429.22% upside)
Analyst Consensus: Buy
Stock Forecasts

News

XPOVIO® (selinexor) Approved for New Indication in DLBCL in China, Bringing a New Treatment Option to Patients in the Country

- Following its initial approval for the treatment of relapsed/refractory multiple myeloma (R/R MM), XPOVIO® has now received approval as a monotherapy for the treatment of adult patients with relapse...

14 days ago - PRNewsWire

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEWTON, Mass. , July 1, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company ...

17 days ago - PRNewsWire

Antengene Announces XPOVIO® (selinexor) National Health Insurance Service Approval for Reimbursement in South Korea

- XPOVIO® is the first XPO1 inhibitor approved for reimbursement by South Korea's National Health Insurance Service (NHIS) for the treatment of adult patients with relapsed/refractory multiple myeloma...

23 days ago - PRNewsWire

Karyopharm Presents Updated Exploratory Subgroup Analyses from SIENDO Study in Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer During 2024 ASCO Plenary Series: Rapid Abstract Updates

Long-Term Follow-Up Data Signal Promising Progression-Free Survival (PFS) for Selinexor in the Maintenance Setting with Median PFS of 28.4 Months in the TP53 Wild-Type and 39.5 Months in the Proficien...

6 weeks ago - PRNewsWire

Karyopharm to Participate at the Jefferies Global Healthcare Conference

NEWTON, Mass. , May 29, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company'...

7 weeks ago - PRNewsWire

Karyopharm to Participate at the 2024 RBC Capital Markets Global Healthcare Conference

NEWTON, Mass. , May 8, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's...

2 months ago - PRNewsWire

Karyopharm Announces Significant Refinancing Transactions and Amended Royalty Agreement Extending Vast Majority of Its Debt Maturities into 2028 and 2029

– $148.0 Million (86%) of Existing Convertible Notes due in 2025 to be Exchanged for $111.0 Million of New Convertible Notes due in 2029 and Warrants – – Issues New $100.0 Million Senior Secured Term ...

2 months ago - PRNewsWire

Karyopharm Reports First Quarter 2024 Financial Results and Highlights Recent Company Progress

– Announces Significant Refinancing Transactions and Amends Royalty Agreement with HealthCare Royalty Extending Vast Majority of Its Debt Maturities into 2028 and 2029, Well Beyond Expected Data Reado...

2 months ago - PRNewsWire

Karyopharm to Report First Quarter 2024 Financial Results on May 8, 2024

-- Conference Call Scheduled for Wednesday, May 8, 2024, at 8:00 a.m. ET -- NEWTON, Mass.

2 months ago - PRNewsWire

Karyopharm Announces Presentations in Endometrial Cancer and Myelofibrosis at the 2024 American Society of Clinical Oncology Annual Meeting

Invited to Present Updated Endometrial Cancer Data During Special Session "ASCO Plenary Series: Rapid Abstract Updates" NEWTON, Mass. , April 24, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nas...

3 months ago - PRNewsWire

Karyopharm to Participate at Barclays 26th Annual Global Healthcare and Leerink Partners Global Biopharma Conferences

NEWTON, Mass. , March 6, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company...

4 months ago - PRNewsWire

Karyopharm Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Company Progress

–  Total Revenue of $146 Million and U.S. XPOVIO® (selinexor) Net Product Revenue of $112 Million for Full Year 2023, Meeting Company's Guidance – – Top-Line Data Readouts from Three Pivotal Phase 3 T...

5 months ago - PRNewsWire

Karyopharm to Report Fourth Quarter and Full Year 2023 Financial Results on February 29, 2024

-- Conference Call Scheduled for Thursday, February 29, 2024, at 8:00 a.m. ET -- NEWTON, Mass.

5 months ago - PRNewsWire

Karyopharm Announces Preliminary Unaudited 2023 Revenue and 2024 Objectives

– Accelerating Innovation and Growth Strategy with Top-Line Data Readouts Expected in 2H 2024 and 2025 from Three Pivotal Phase 3 Studies Evaluating Selinexor in Multiple Myeloma, Endometrial Cancer a...

6 months ago - PRNewsWire

Karyopharm to Present at 42nd Annual J.P. Morgan Healthcare Conference

NEWTON, Mass. , Jan. 3, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company'...

7 months ago - PRNewsWire

Antengene Announces Inclusion of XPOVIO® (selinexor) in 2023 China's National Reimbursement Drug List

SHANGHAI and HONG KONG , Dec. 13, 2023 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to d...

7 months ago - PRNewsWire

Karyopharm Shares Data at ASH 2023 Showing Strong SVR and TSS Durability Observed from Phase 1 Study of Selinexor 60mg and Ruxolitinib in JAK Inhibitor (JAKi)-Naïve Myelofibrosis Patients, with no SVR or TSS Progressions Observed As of the Data Cutoff(1)

Biomarker Data from Phase 1 Study of Selinexor in Combination with Ruxolitinib in Treatment-Naïve Myelofibrosis (MF) Suggestive of Disease Modification Data Reinforce the Potential for Selinexor in Co...

7 months ago - PRNewsWire

Antengene Announces XPOVIO® Regulatory Approval in Macau for the Treatment of Relapsed and/or Refractory Multiple Myeloma

XPOVIO® (selinexor) is the first and only exportin 1 (XPO1) inhibitor approved in Macau.  XPOVIO® has received regulatory approvals in   42 countries and regions including Mainland of China, Taiwan Ch...

8 months ago - PRNewsWire

Karyopharm to Participate at Upcoming Investor Conferences

NEWTON, Mass. , Nov. 8, 2023 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company'...

9 months ago - PRNewsWire

Karyopharm Announces New Preliminary Data in Overall Survival (OS) in Selinexor-Treated Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer as Part of Pre-Specified Exploratory Subgroup Analysis of the SIENDO Study

Long-Term Safety and Efficacy Data from SIENDO Study in the TP53 Wild-Type Exploratory Subgroup Showed Signals of Improvement in Overall Survival  (OS) Regardless of Mismatched Repair Status (MMR) Med...

9 months ago - PRNewsWire

Karyopharm Announces Presentations at the 65th American Society of Hematology Annual Meeting and Exposition (ASH)

Long-Term Selinexor Data in Myelofibrosis will be Presented as Part of Oral Presentation NEWTON, Mass. , Nov. 2, 2023 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage ph...

9 months ago - PRNewsWire

Karyopharm Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress

– Achieved Third Quarter 2023 Total Revenue of $36.0 Million and U.S. XPOVIO® (selinexor) Net Product Revenue of $30.2 Million – –  Maintains Full Year 2023 Total Revenue Guidance of $145 Million to $...

9 months ago - PRNewsWire

Karyopharm Announces Clinical Trial Collaboration with Bristol Myers Squibb to Evaluate Novel CELMoD™ Agent CC- 92480 Mezigdomide in Combination with Selinexor in Patients with Relapsed/Refractory Multiple Myeloma

—  Phase 1b/2 Trial Will Investigate Mezigdomide in Combination with  Selinexor  in Patients with Relapsed/Refractory Multiple Myeloma Progressing after T-cell Immunotherapies – — Expected to be Initi...

Other symbols: BMY
9 months ago - PRNewsWire

Karyopharm to Report Third Quarter 2023 Financial Results on November 2, 2023

-- Conference Call Scheduled for Thursday, November 2, 2023, at 8:00 a.m. ET -- NEWTON, Mass.

9 months ago - PRNewsWire

Karyopharm to Present Selinexor Data at the 2023 International Myeloma Society Annual Meeting and European Society of Gynaecological Oncology 2023 Annual Meetings

NEWTON, Mass. , Sept. 26, 2023 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that several ab...

10 months ago - PRNewsWire